FinnCap restated their corporate rating on shares of Bioventix PLC (LON:BVXP) in a research report released on Tuesday. FinnCap currently has a GBX 2,600 ($34.20) price target on the biotechnology company’s stock.
Bioventix PLC (BVXP) opened at GBX 2,650 ($34.85) on Tuesday. Bioventix PLC has a 1-year low of GBX 26.51 ($0.35) and a 1-year high of GBX 2,950 ($38.80).
The company also recently declared a dividend, which was paid on Friday, November 10th. Shareholders of record on Thursday, October 26th were issued a dividend of GBX 71 ($0.93) per share. The ex-dividend date of this dividend was Thursday, October 26th. This represents a yield of 2.67%. This is an increase from Bioventix PLC’s previous dividend of $20.00.
COPYRIGHT VIOLATION NOTICE: “FinnCap Reiterates “Corporate” Rating for Bioventix PLC (BVXP)” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/11/25/finncap-reiterates-corporate-rating-for-bioventix-plc-bvxp.html.
Bioventix PLC Company Profile
Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.
Receive News & Ratings for Bioventix PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix PLC and related companies with MarketBeat.com's FREE daily email newsletter.